Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Breast Cancer

Free Subscription 03.08.2026 1 AJR Am J Roentgenol 1 Am J Pathol 1 Ann Oncol 11 Ann Surg Oncol 4 Anticancer Res 2 BMC Cancer 5 Br J Cancer 1 Breast Cancer 1 Breast Cancer (Auckl) 6 Breast Cancer (Dove Med Press) 8 Breast Cancer Res Treat 1 Breast J 2 Cancer 1 Carcinogenesis 8 Clin Breast Cancer 1 Clin Cancer Res 1 Clin Med Insights Oncol 1 Exp Cell Res 1 Int J Cancer 2 Int J Radiat Oncol Biol Phys 1 J Clin Invest 1 J Clin Oncol 3 J Natl Cancer Inst 1 J Surg Oncol 2 Lancet Oncol 1 Oncology (Williston Park) 1 PLoS Comput Biol 3 PLoS One 1 Radiol Artif Intell 1 Radiol Imaging Cancer 1 Radiology

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

AJR Am J Roentgenol

1. 
   Correction for: "Baseline and Early Treatment MRI Model for Predicting Complete Pathologic Response to Neoadjuvant Chemoimmunotherapy in Patients With Triple-Negative Breast Cancer".
   AJR Am J Roentgenol. 2026 Jul 29:1. doi: 10.2214/AJR.26.35354.
   PubMed        
   
   

   
   Am J Pathol

2. HUI H, DuCasse A, Jones D
   Tumor Microenvironmental Barriers to T Cell Infiltration in Breast Cancer.
   Am J Pathol. 2026 Jul 27:S0002-9440(26)00203.
   PubMed         Abstract available
   
   

   
   Ann Oncol

3. JURIC D, Rugo HS, Reising A, Vervier K, et al
   Genomic determinants of response to alpelisib plus fulvestrant in the SOLAR-1 trial.
   Ann Oncol. 2026;37:1106-1119.
   PubMed         Abstract available
   
   

   
   Ann Surg Oncol

4. KAWASHIMA K, Chida K, Oshi M, Yamada A, et al
   A Neuron Projection Guidance Signature Associates with Immune-Cold Tumor Microenvironment and Poor Outcomes in Breast Cancer.
   Ann Surg Oncol. 2026 Jul 25. doi: 10.1245/s10434-026-19932.
   PubMed         Abstract available
   
   
5. KORSHOLM RHR, Kroman N, Tvedskov THF, Munck F, et al
   ASO Visual Abstract: Axillary Recurrence and Survival After Omission of Axillary Lymph Node Dissection in Patients with Breast Cancer and Micrometastases or Isolated Tumor Cells in the Sentinel Node: A Danish National Register Study.
   Ann Surg Oncol. 2026 Jul 27. doi: 10.1245/s10434-026-20234.
   PubMed        
   
   
6. LI K, Zhang Y, Liu Z, Wang S, et al
   Global Inequalities in Female Breast Cancer Burden by Decomposition and Age-Period-Cohort Analysis, 1990-2021.
   Ann Surg Oncol. 2026 Jul 28. doi: 10.1245/s10434-026-19798.
   PubMed         Abstract available
   
   
7. SETO A, Port E, Bernik S, Sheng T, et al
   ASO Visual Abstract: Preoperative Radiologic Assessment of the Axilla in Locally Advanced Breast Cancer After Neoadjuvant Systemic Therapy: A Contemporary comparison.
   Ann Surg Oncol. 2026 Jul 28. doi: 10.1245/s10434-026-20332.
   PubMed        
   
   
8. LATTIMORE CM, Johnson HM
   ASO Author Reflections: Rethinking Local Therapy for Occult Breast Cancer with Advanced Nodal Disease.
   Ann Surg Oncol. 2026 Jul 29. doi: 10.1245/s10434-026-20299.
   PubMed        
   
   
9. BLACK DM, Glasgow AE, Degnim AC, Hieken TJ, et al
   Contralateral Prophylactic Mastectomy in Women with Unilateral Breast Cancer by Age, Race, and Tumor Subtype.
   Ann Surg Oncol. 2026 Jul 29. doi: 10.1245/s10434-026-20306.
   PubMed         Abstract available
   
   
10. WAGNER BD, Chen J, Boe LA, Graziano FD, et al
    Using Machine Learning to Predict Breast Cancer-Related Lymphedema Following Axillary Lymph Node Dissection.
    Ann Surg Oncol. 2026 Jul 29. doi: 10.1245/s10434-026-20309.
    PubMed         Abstract available
    
    
11. PITSINIS V, Khitab N, Jordan L, Vinci A, et al
    ICG-only Sentinel Lymph Node Biopsy in Breast Cancer: A Prospective UK Cohort Demonstrating Consistent Detection Across Patient and Tumour Characteristics-A Follow-on to the INFLUENCE Trial.
    Ann Surg Oncol. 2026 Jul 29. doi: 10.1245/s10434-026-20316.
    PubMed         Abstract available
    
    
12. BAE SJ, Lee J, Do SI, Kim EY, et al
    ASO Visual Abstract: Risk of pN2/3 Understaging in Sentinel Node-Positive ER+/HER2- Breast Cancer: A Composite Clinicopathologic Score for Safe RxPONDER and MonarchE Application.
    Ann Surg Oncol. 2026 Jul 31. doi: 10.1245/s10434-026-20321.
    PubMed        
    
    
13. TSENG J, Dimitroff K, Sauder CAM, Chien AJ, et al
    ASO Visual Abstract: Surgical Management of Young Women with High-Risk Breast Cancer Receiving Neoadjuvant Systemic Therapy in the I-SPY2 Trial.
    Ann Surg Oncol. 2026 Jul 31. doi: 10.1245/s10434-026-20217.
    PubMed        
    
    
14. KOPKASH K, Hwang R
    ASO Author Reflections: The Role of the Robot for Early-Stage Breast Cancer Patients Undergoing Nipple-Sparing Mastectomy.
    Ann Surg Oncol. 2026 Jul 30. doi: 10.1245/s10434-026-20343.
    PubMed        
    
    

    
    Anticancer Res

15. FOO CY, Sehrawat O, Puri A, Haque W, et al
    Disparities in Palliative Care Utilization in Metastatic Triple-negative Breast Cancer: A National Cancer Database Study.
    Anticancer Res. 2026;46:4385-4392.
    PubMed         Abstract available
    
    
16. HAN KH, Kim AK, Bhang SH, Kim DI, et al
    Parabiosis Suppresses Breast Tumor Growth With Increased Effector Memory T Cells and HSPB3.
    Anticancer Res. 2026;46:4203-4220.
    PubMed         Abstract available
    
    
17. SUZUKI M, Furusawa A, Yamamoto H, Kitamura KO, et al
    Near-infrared Photoimmunotherapy Targeting Canine Mammary Tumors: Comparative Oncology for Overcoming Human Breast Cancer.
    Anticancer Res. 2026;46:4171-4182.
    PubMed         Abstract available
    
    
18. CHUNG Y, Kim HS, DO SI
    Aberrant E-cadherin Expression in Invasive Ductal and Mixed Ductal-Lobular Breast Carcinomas.
    Anticancer Res. 2026;46:4345-4356.
    PubMed         Abstract available
    
    

    
    BMC Cancer

19. AL-QERSHI O, Nguyen TL, Elliott MS, Schmidt DF, et al
    AutoCumulus: an automated mammographic density measure created using artificial intelligence.
    BMC Cancer. 2026;26:900.
    PubMed         Abstract available
    
    
20. RABANI F, Samadi MH, Sadeghpour S, Barashki S, et al
    [(1)(7)(7)Lu]Lu-FAPI-2286 radioligand therapy in heavily pre-treated patients with advanced breast and gastrointestinal cancers: a single-center retrospective experience.
    BMC Cancer. 2026;26:905.
    PubMed         Abstract available
    
    

    
    Br J Cancer

21. JEONG JY, Kim CY, Nam AR, Cho JY, et al
    FGFR4-associated APOBEC3 mutagenesis characterizes HER2-enriched subtype of human breast cancer.
    Br J Cancer. 2026 Jul 27. doi: 10.1038/s41416-026-03517.
    PubMed         Abstract available
    
    
22. LOPEZ MUJICA MEJ, Boonkaew S, Christensen NL, Abildgaard Pedersen M, et al
    Differentiating borderline HER2-expressing and HER2-positive cancers from other subtypes using serum urokinase plasminogen activator.
    Br J Cancer. 2026;135:649-658.
    PubMed         Abstract available
    
    
23. LI SJ, Brentnall AR, Cookson J, Hudson S, et al
    The effect of different combinations of open invitations and timed appointments on breast screening attendance: service evaluation of invitation strategies in the NHS Breast Screening Programme.
    Br J Cancer. 2026;135:630-640.
    PubMed         Abstract available
    
    
24. YANG K, Thong MSY, Doege D, Koch-Gallenkamp L, et al
    Diabetes mellitus and health-related quality of life in long-term survivors of breast, colorectal or prostate cancer: a population-based prospective study.
    Br J Cancer. 2026 May 13. doi: 10.1038/s41416-026-03463.
    PubMed         Abstract available
    
    
25. KANG MS, Katuwal NB, Ghosh M, Hong SD, et al
    JPI-547, a novel dual inhibitor of PARP1/2 and tankyrase is more effective than first-generation PARP inhibitors in preclinical BRCA1/2-mutated cancer models.
    Br J Cancer. 2026;135:503-517.
    PubMed         Abstract available
    
    

    
    Breast Cancer

26. DEL ARCO A, Garcia-Chico C, Khoramipour K, Castaneda-Babarro A, et al
    Effect of exercise based prehabilitation on postoperative pain in breast cancer patients: a systematic review with meta-analysis.
    Breast Cancer. 2026 Jul 30. doi: 10.1007/s12282-026-01899.
    PubMed         Abstract available
    
    

    
    Breast Cancer (Auckl)

27. 
    Expression of concern: "Novel Melatonin, Estrogen, and Progesterone Hormone Therapy Demonstrates Anti-Cancer Actions in MCF-7 and MDA-MB-231 Breast Cancer Cells".
    Breast Cancer (Auckl). 2026;20:11782234261466757.
    PubMed        
    
    

    
    Breast Cancer (Dove Med Press)

28. LI H, Cheng Y, Meng Y, Nan L, et al
    Suppressing M2 Macrophage Polarization by Glycine Combined with beta-Elemene via the IL-6/JAK2/STAT3 Signaling Pathway to Inhibit Triple-Negative Breast Cancer Progression.
    Breast Cancer (Dove Med Press). 2026;18:626034.
    PubMed         Abstract available
    
    
29. KONG L, Zhang H, Sui X, Peng X, et al
    miR-1911-3p Regulates Malignant Biological Behaviors and Glycolytic Activity of Triple-Negative Breast Cancer via FBLN5.
    Breast Cancer (Dove Med Press). 2026;18:615715.
    PubMed         Abstract available
    
    
30. WANG X, Zhao Y, Peng S, Wang X, et al
    Lipid Metabolic Reprogramming in Breast Cancer: Mechanisms and Emerging Therapeutic Strategies.
    Breast Cancer (Dove Med Press). 2026;18:591634.
    PubMed         Abstract available
    
    
31. GOKDERE ZS, Gunenc D, Sezer S, Gecgel A, et al
    Prognostic Significance of Pretreatment Mean Platelet Volume in Patients with Recurrent or De Novo Metastatic Breast Cancer: A Single-Center Retrospective Study.
    Breast Cancer (Dove Med Press). 2026;18:629176.
    PubMed         Abstract available
    
    
32. AYDIN B, Okutan BN, Sara FE, Gulseren G, et al
    Integrative Network-Based Transcriptomic Analysis Identifies Niclosamide as a Candidate Repositioned Drug for Breast Cancer.
    Breast Cancer (Dove Med Press). 2026;18:606551.
    PubMed         Abstract available
    
    
33. ZHAO D, Tan Z, Chen W, Liu S, et al
    Long Non-Coding RNA PVT1 Promotes Doxorubicin Resistance by Inhibiting Ferroptosis in Breast Cancer.
    Breast Cancer (Dove Med Press). 2026;18:583235.
    PubMed         Abstract available
    
    

    
    Breast Cancer Res Treat

34. LIU B, Wu T, Ding S, Liu X, et al
    Machine learning and cox model-based prediction of CDK4/6 inhibitor outcomes in HR+/HER2 - metastatic breast cancer: a multicenter real-world study.
    Breast Cancer Res Treat. 2026;218:27.
    PubMed         Abstract available
    
    
35. NIRAVATH P, Rimawi M, Sun K, Mai H, et al
    VEMORA: Vaginal Estrogen versus non-hormonal MOisturizer in women Receiving Aromatase inhibitors: a randomized, controlled trial.
    Breast Cancer Res Treat. 2026;218:25.
    PubMed         Abstract available
    
    
36. TESCH ME, Graham N, Snow C, Stever CE, et al
    Association between self-reported breast cancer knowledge and clinical trial participation in patients with triple-negative breast cancer.
    Breast Cancer Res Treat. 2026;218:26.
    PubMed         Abstract available
    
    
37. ANUSZKIEWICZ K, Ekman M, Graczyk M, Drozd M, et al
    Correction: Correlation between the drainage time in dynamic indocyanine green lymphography (ICG) and axillary lymph nodes metastatic involvement in breast cancer patients-a prospective study.
    Breast Cancer Res Treat. 2026;218:23.
    PubMed        
    
    
38. ZAYHOWSKI K, Blumen K, Mittendorf KF, Pratt R, et al
    Healthcare professional perspectives on hereditary breast cancer risk assessment prior to gender-affirming mastectomy.
    Breast Cancer Res Treat. 2026;218:22.
    PubMed         Abstract available
    
    
39. BOLDRINI C, Bottalico M, Lia FL, Longo V, et al
    Assisted Reproductive Technologies (ART) and breast cancer risk: hormonal treatments under the spotlight.
    Breast Cancer Res Treat. 2026;218:24.
    PubMed         Abstract available
    
    
40. WATANABE C, Kashiwagi S, Nishikawa M, Kochi A, et al
    Clinical and imaging factors associated with prolonged ablation time in radiofrequency ablation for early-stage breast cancer.
    Breast Cancer Res Treat. 2026;218:21.
    PubMed         Abstract available
    
    
41. LEENHARDT F, Jacot W, Lellouche L, Guiu S, et al
    Antacid co-treatment and pregnane X receptor genetic polymorphisms are survival determinants in patients treated with palbociclib.
    Breast Cancer Res Treat. 2026;218:20.
    PubMed         Abstract available
    
    

    
    Breast J

42. CONROY S, Keane E, Rehman B, Wyborn E, et al
    Implementation and Audit of Mainstream Genetic Testing Within a High-Volume UK Breast Unit for Pathogenic Variations Associated With Breast Cancer Using the R208 and R444.1 National Test Directory Criterion.
    Breast J. 2026;2026:e2657384.
    PubMed         Abstract available
    
    

    
    Cancer

43. LAWRENCE L
    New data inform decision-making for breast cancer surgeries: Two studies presented at the American Society of Breast Surgeons Annual Meeting provide new comparative outcome data.
    Cancer. 2026;132:e70488.
    PubMed        
    
    
44. ZHOU Y, Liu J, Fu X, Fan J, et al
    Early neural signatures of cancer-related fatigue: A longitudinal magnetic resonance imaging study of cortical micro- and macrostructural changes during breast cancer chemotherapy.
    Cancer. 2026;132:e70558.
    PubMed         Abstract available
    
    

    
    Carcinogenesis

45. 
    Retraction: miR-720 inhibits tumor invasion and migration in breast cancer by targeting TWIST1.
    Carcinogenesis. 2026 Jul 29:bgag041. doi: 10.1093.
    PubMed        
    
    

    
    Clin Breast Cancer

46. LUO S, Lai H, Zhao J, Zeng Y, et al
    Comparison of Clinicopathological Features and Survival Between Distant Lymph Node Metastasis and Distant Micrometastasis in Breast Cancer.
    Clin Breast Cancer. 2026;26:137-144.
    PubMed         Abstract available
    
    
47. CHONG EG, Guo M, Bera K, Castillo D, et al
    Evaluating the Efficacy of Neoadjuvant Endocrine Therapy in HER2-Low Versus HER2-Negative Breast Cancer.
    Clin Breast Cancer. 2026;26:189-195.
    PubMed         Abstract available
    
    
48. KNUDSEN BM, Sondergaard SR, Lund L, Steffensen KD, et al
    Impact of Timing and Format of Patient Decision Aids on Involvement in Shared Decision-Making for Patients With Breast Cancer: The IMPACTT Randomized, Controlled Study.
    Clin Breast Cancer. 2026;26:180-188.
    PubMed         Abstract available
    
    
49. DENG T, Xiang H, Luo X, Yan C, et al
    Comparative Prognostic Utility of CPS+EG, Neo-Bioscore, and Conventional Staging Systems in Breast Cancer Patients Without Pathological Complete Response to Neoadjuvant Chemotherapy.
    Clin Breast Cancer. 2026;26:172-179.
    PubMed         Abstract available
    
    
50. SAMAI N, Berremdani A
    Prognostic Value of Estrogen Receptors Versus Progesterone Receptors in Early Breast Cancer: An Analysis of Clinical and Translational Data (2004-2026).
    Clin Breast Cancer. 2026;26:165-171.
    PubMed         Abstract available
    
    
51. NILSEN OJ, Williams DS, Tsao CS, White S, et al
    Real-World Feasibility Assessment of Short-Course Preoperative Endocrine Therapy Using the Ki67 Biomarker in an Australian Cohort of Patients With Estrogen Receptor-Positive Early Breast Cancer.
    Clin Breast Cancer. 2026;26:158-164.
    PubMed         Abstract available
    
    
52. TARIQ F, Taylor T, Bastaich D, Sheppard VB, et al
    Assessing Racial Differences in Psychological Distress and Problem Items among Breast Cancer Survivors at Adjuvant Endocrine Therapy Initiation.
    Clin Breast Cancer. 2026;26:131-136.
    PubMed         Abstract available
    
    
53. YEH MH, Li CW, Chen L, Shih TY, et al
    Heterozygous BRCA1 SNPs in the Central Functional Region are Associated With Increased Sensitivity to PARP Inhibition in Breast Cancer Cells.
    Clin Breast Cancer. 2026;26:121-130.
    PubMed         Abstract available
    
    

    
    Clin Cancer Res

54. ZHAO SG, Holmberg E, Lundstedt D, Killander F, et al
    Investigation of a prostate cancer radiation response signature in the breast cancer SweBCG91RT randomized trial.
    Clin Cancer Res. 2026 Jul 30. doi: 10.1158/1078-0432.CCR-26-1455.
    PubMed         Abstract available
    
    

    
    Clin Med Insights Oncol

55. AZAM F, Momtaz T, Islam F, Rahman KF, et al
    Combination Therapy, Drug Interactions, and Survival Outcomes in Metastatic Breast Cancer: A Pooled Analysis of Phase II Trials.
    Clin Med Insights Oncol. 2026;20:11795549261473457.
    PubMed         Abstract available
    
    

    
    Exp Cell Res

56. DU Y, Ning D, Yu J, Chen Y, et al
    Neddylation cooperates with multiple phosphorylation to enhance FGFR1 stability and drive breast cancer progression.
    Exp Cell Res. 2026;462:115141.
    PubMed         Abstract available
    
    

    
    Int J Cancer

57. MA Y, Chen D, Huang S
    De-Escalation of Neoadjuvant Treatment for HER2-Positive Breast Cancer.
    Int J Cancer. 2026 Jul 28. doi: 10.1002/ijc.70614.
    PubMed         Abstract available
    
    

    
    Int J Radiat Oncol Biol Phys

58. JAGSI R, Meisner A, Chalasani P, Lew D, et al
    Adverse Events in a Randomized Trial Comparing Radiotherapy with or without Olaparib for Inflammatory Breast Cancer.
    Int J Radiat Oncol Biol Phys. 2026 Jul 28:S0360-3016(26)04066.
    PubMed         Abstract available
    
    
59. SALOME P, Shah KD, Todorova P, DePauw N, et al
    Differential lung tissue response and patient outcomes between protons and photons receiving regional nodal irradiation for breast cancer: A Prospective Correlative Study within a Randomized Trial.
    Int J Radiat Oncol Biol Phys. 2026 Jul 29:S0360-3016(26)04058.
    PubMed         Abstract available
    
    

    
    J Clin Invest

60. AWADIA S, Ziemke EK, Curnutt NM, Kirk E, et al
    Targeting casein kinase 1alpha-mediated FADD phosphorylation restores sensitivity in select CDK4/6 inhibitor-resistant breast cancer models.
    J Clin Invest. 2026 Jul 28:e199483. doi: 10.1172/JCI199483.
    PubMed         Abstract available
    
    

    
    J Clin Oncol

61. GANDINI S, Guerrieri-Gonzaga A, Serrano D, Rizzo R, et al
    Low-Dose Tamoxifen in Noninvasive Breast Neoplasia: Long-Term Results From an Individual-Participant Data Pooled Analysis.
    J Clin Oncol. 2026;44:2121-2129.
    PubMed         Abstract available
    
    

    
    J Natl Cancer Inst

62. ROUSSEL-SIMONIN C, Rassy E
    The unfinished story of pregnancy-associated breast cancer.
    J Natl Cancer Inst. 2026 Jul 25:djag191. doi: 10.1093.
    PubMed        
    
    
63. PATEL R, Kwa M, Klein P, Fasano J, et al
    A multicenter, phase I/II trial of anastrozole, palbociclib, trastuzumab, and pertuzumab in hormone receptor (HR)-positive, HER2-positive metastatic breast cancer (ASPIRE).
    J Natl Cancer Inst. 2026 Jul 30:djag256. doi: 10.1093.
    PubMed         Abstract available
    
    
64. JI J, Sun CL, Dale W, Cohen HJ, et al
    Early discontinuation of chemotherapy in older adults with early breast cancer: results from the prospective multicenter HOPE study.
    J Natl Cancer Inst. 2026 Jul 30:djag250. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    J Surg Oncol

65. PROUSSALOGLOU EM, Ren Y, Fayanju OM, Blitzblau RC, et al
    Patient Out-of-Pocket Costs and Healthcare Utilization Related to Mastectomy vs Breast Conservation: A Claims-Based Study.
    J Surg Oncol. 2026;134:185-196.
    PubMed         Abstract available
    
    

    
    Lancet Oncol

66. HANNOUN-LEVI JM, Margenthaler JA, Anderson B, Di Micco R, et al
    Local management of second ipsilateral breast cancer events after primary breast-conserving therapy: an international Delphi consensus.
    Lancet Oncol. 2026 Jul 29:S1470-2045(26)00177.
    PubMed         Abstract available
    
    
67. VELIKOVA G, Russell NS, Williams LJ, Pollock R, et al
    Postmastectomy chest wall radiotherapy for breast cancer (SUPREMO): 5-year quality-of-life results from a randomised, controlled, phase 3 trial.
    Lancet Oncol. 2026;27:959-972.
    PubMed         Abstract available
    
    

    
    Oncology (Williston Park)

68. OMENE C
    Advancing Multidisciplinary Care and Health Equity in Metastatic Breast Cancer.
    Oncology (Williston Park). 2026;40.
    PubMed         Abstract available
    
    

    
    PLoS Comput Biol

69. STANCIU A, Gombos A, Agostinetto E, Vincent D, et al
    ALFAssay: A feed?forward neural network for quantitative fragmentomics?based ctDNA profiling in breast cancer.
    PLoS Comput Biol. 2026;22:e1014505.
    PubMed         Abstract available
    
    

    
    PLoS One

70. KHADKA S, Thornton JD, Kamal KM, Higa G, et al
    Pattern of opioid prescriptions among patients with breast, lung, and colorectal cancer diagnosed with pre-existing chronic non-cancer pain.
    PLoS One. 2026;21:e0352907.
    PubMed         Abstract available
    
    
71. OKYERE F, Nyanney M
    Stability and interpretability of penalized logistic regression models for breast cancer risk prediction.
    PLoS One. 2026;21:e0353489.
    PubMed         Abstract available
    
    
72. FUCHS P, Reumueller A, Kreminger J, Zafeiri E, et al
    Choroidal metastasis: Impact of primary tumors and age on survival - a single center analysis.
    PLoS One. 2026;21:e0354598.
    PubMed         Abstract available
    
    

    
    Radiol Artif Intell

73. ZHOU Z, Arefan D, Zuley ML, Sumkin JH, et al
    Spatiotemporal Asymmetries of Longitudinal Screening Mammograms for Breast Cancer Risk Prediction.
    Radiol Artif Intell. 2026 Jul 29:e250888. doi: 10.1148/ryai.250888.
    PubMed         Abstract available
    
    

    
    Radiol Imaging Cancer

74. BREEN R, Chung M
    AI-based Triage in Breast Cancer Screening Reduces Workload with Noninferior Cancer Detection but Higher Recall.
    Radiol Imaging Cancer. 2026;8:e269018.
    PubMed        
    
    

    
    Radiology

75. LEE CH, Amir T, Sevilimedu V, Eskreis-Winkler S, et al
    Contrast-enhanced Mammography for Breast Cancer Screening in Women at Increased Risk: Comparison of Prevalence and Incidence Screens.
    Radiology. 2026;320:e252433.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum